Disclaimer: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

December 19, 2025

Company Name gumi Inc.
Representative Hiroyuki Kawamoto, Representative Director
(Code: 3903; Prime Market of the Tokyo Stock Exchange)
Inquiries Makoto Motoyoshi, Director
(TEL. +81-3-5358-5322)

Notice Regarding Investment in a U.S. AI Startup

gumi Inc. (the "Company") hereby announces that its subsidiary, gumi America, Inc., has completed an investment in Anto Biosciences, Inc. (hereinafter, "Anto Biosciences"), a U.S. startup which develops AI foundation models to predict the interactions between the human microbiome and drug metabolism.

Anto Biosciences

1. Background and Purpose of the Investment

The Company recognizes that advances in AI technology are driving structural transformation across all industries. The implementation of AI technology in society is key to productivity gains and new value creation, and the Company believes its importance will increase markedly in future corporate activities. Through this investment, the Company aims to acquire knowledge in the AI sector and explore future revenue opportunities, while also striving to enhance medium-to-long-term corporate value.

2. Overview of the Investee

Unlike conventional startups that develop "live biotherapeutics" themselves using microbes, Anto Biosciences provides a "drug discovery support platform" to pharmaceutical companies to reduce drug development risk. Anto Biosciences' AI model enables pharmaceutical companies to predict and optimize the risk of traditional small-molecule compounds and biologics being metabolized or degraded due to microbial interference. In fact, Anto Biosciences' analysis successfully identified that the cause of a "$1 billion (approx. 150 billion yen) cancer drug," which was effective in China but failed in U.S. clinical trials, lay in the differences in the microbiome across population groups, and successfully presented a solution. The demand for such technology, which can bridge microbiome

differences across countries and regions and regenerate failed therapies, is expected to be extremely high among global pharmaceutical companies.

In this way, Anto Biosciences has established a unique position by providing predictive models to enhance the success rate of drug discovery, rather than creating the drugs themselves. The strengths of Anto Biosciences are as follows:

- Unique Position as a Drug Discovery Support Platform
  Instead of undertaking high-risk new drug development itself, Anto Biosciences generates stable and widespread revenue opportunity by providing pharmaceutical companies with an analytical platform to optimize existing small-molecule drugs and biologics.
- Proprietary Data Compression Technology "Sparsification"
  The algorithm developed by CEO Gollwitzer achieves high prediction accuracy while reducing massive and noisy microbial genomic data by 99%. This enables high-speed computation and model construction at a scale impossible for competitors.
- Avoidance and Regeneration of "Drug Discovery Failures" Due to Regional Differences
  By analyzing differences in the microbiome across population groups, Anto Biosciences can clarify the cause of drugs that "succeeded in one country but failed in another." This allows pharmaceutical companies to redevelop (revive) promising drugs that were previously discontinued for specific markets or patient groups.

Anto Biosciences was selected for the latest batch (Fall 2025) of the world-leading startup accelerator, "Y Combinator," which has incubated companies such as Airbnb and Stripe. Anto Biosciences' founding team possesses outstanding track records in the fusion of high-performance computing and biology. CEO Arvid Ernst Gollwitzer founded Anto Biosciences after serving as a researcher at the MIT-Harvard Broad Institute, MIT, and ETH Zurich. The "sparsification" technology he specializes in is an algorithm that reduces noisy genomic data by 99% while maintaining predictive accuracy, and it is the core technology that made Anto Biosciences' model feasible while competitors struggled with computational cost barriers. Furthermore, David de Gruijl, who oversees the Biology and Medical division, has a career that includes research in gastroenterology at Harvard Medical School, in addition to positions at Johnson & Johnson and the Swiss Federal Institute of Technology in Zurich (ETH Zurich). He possesses deep expertise in the interaction between drugs and the gut environment and is well-versed in the structural challenges and failure points in pharmaceutical R&D settings.

Company Overview

Name	Anto Biosciences, Inc.
Address	San Francisco, California, USA
Representative	CEO Arvid Ernst Gollwitzer
Business Description	Development and provision of an AI foundation model that predicts drug metabolism based on the microbiome.
URL	https://www.anto.bio/